Fulton Bank N.A. Increases Stock Position in Merck & Co., Inc. $MRK

Fulton Bank N.A. grew its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 19.8% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 78,112 shares of the company’s stock after acquiring an additional 12,897 shares during the period. Fulton Bank N.A.’s holdings in Merck & Co., Inc. were worth $9,396,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Norges Bank purchased a new position in Merck & Co., Inc. in the fourth quarter valued at about $3,997,933,000. Wellington Management Group LLP raised its position in shares of Merck & Co., Inc. by 14.8% in the 4th quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company’s stock valued at $9,098,196,000 after purchasing an additional 11,156,354 shares in the last quarter. DLD Asset Management LP raised its position in shares of Merck & Co., Inc. by 30.1% in the 3rd quarter. DLD Asset Management LP now owns 47,500,000 shares of the company’s stock valued at $3,986,675,000 after purchasing an additional 11,000,000 shares in the last quarter. Cardano Risk Management B.V. purchased a new position in shares of Merck & Co., Inc. during the 4th quarter valued at approximately $1,012,530,000. Finally, Jennison Associates LLC purchased a new position in shares of Merck & Co., Inc. during the 4th quarter valued at approximately $585,192,000. 76.07% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

MRK has been the subject of a number of research analyst reports. Wall Street Zen upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Saturday, June 6th. Bank of America boosted their price objective on Merck & Co., Inc. from $130.00 to $141.00 and gave the company a “buy” rating in a report on Tuesday. Royal Bank Of Canada restated an “outperform” rating and set a $142.00 price objective on shares of Merck & Co., Inc. in a research note on Monday, March 30th. Zacks Research raised Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 17th. Finally, CICC Research initiated coverage on Merck & Co., Inc. in a report on Wednesday, June 24th. They set an “outperform” rating and a $138.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $131.83.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Bank of America raised its price target on Merck to $141 from $130 and reiterated a buy rating, citing improved upside potential. Bank of America raises Merck price target
• Positive Sentiment: Scotiabank lifted its price target to $155 from $136 and maintained an outperform rating, signaling stronger confidence in Merck’s valuation and earnings outlook. Scotiabank raises Merck price target
• Positive Sentiment: Erste Group slightly increased its FY2027 EPS estimate for Merck, reflecting modestly improved long-term earnings expectations. Erste Group EPS estimate update
• Positive Sentiment: Merck announced it will hold its second-quarter 2026 sales and earnings conference call on Aug. 4, keeping investors focused on upcoming results and guidance. Merck earnings conference call announcement
• Neutral Sentiment: Merck also hit a new 52-week high following the analyst upgrade, but the stock has since pulled back after its six-day advance, suggesting some profit-taking. Merck sets new 52-week high on analyst upgrade
• Negative Sentiment: U.S. lawmakers launched a national security probe into Merck’s clinical trial activities in China, raising concerns about data protection, oversight, and exposure to politically sensitive trial sites. Merck faces U.S. security probe over China clinical trials
• Negative Sentiment: Broader healthcare weakness also weighed on sentiment, with the sector lower late Tuesday afternoon. Healthcare stocks softer late afternoon

Merck & Co., Inc. Price Performance

Shares of NYSE:MRK opened at $125.30 on Thursday. The company has a market cap of $309.46 billion, a PE ratio of 35.29, a P/E/G ratio of 2.62 and a beta of 0.19. Merck & Co., Inc. has a fifty-two week low of $76.66 and a fifty-two week high of $130.29. The firm has a 50-day simple moving average of $116.71 and a 200 day simple moving average of $115.06. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The firm had revenue of $16.29 billion for the quarter, compared to analysts’ expectations of $15.85 billion. During the same quarter last year, the company posted $2.22 earnings per share. Merck & Co., Inc.’s revenue was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, sell-side analysts anticipate that Merck & Co., Inc. will post 5.19 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 8th. Investors of record on Monday, June 15th will be issued a $0.85 dividend. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.7%. Merck & Co., Inc.’s dividend payout ratio (DPR) is 95.77%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.